bioimagesUnknownAshraf Yusuf RangrezThe Journal of Cell Biologyhttps://www.ebi.ac.uk/biostudies/studies/S-JCBD-201303052JCB

A representative image exemplifying the phenotype of control, phenylephrine-treated neonatal rat cardiomyocytes (NRVCMs) is shown. NRVCMs were cultured on coverslips in triplicate, infected with Ad-LacZ for 72 hr, treated with phenylephrine, and immunostained with α-actinin (red). Nuclei were stained with DAPI (blue).

Co-immunostaining of Dysbindin (red) with RhoA (green) in endothelin-1-treated neonatal rat cardiomyocytes (NRVCMs). Nuclei were stained with DAPI (blue), and the immunofluorescence images were captured on a Zeiss LSM 510 confocal microscope.

Co-immunostaining of Dysbindin (red) with Myozap (green) in adult rat cardiomyocytes (ARVCMs) is shown. Nuclei were stained with DAPI (blue), and the immunofluorescence images were captured in a Zeiss LSM 510 confocal microscope.

A representative image exemplifying the phenotype of MEK1 inhibitor-treated neonatal rat cardiomyocytes infected with Ad-Dysbindin is shown.

Co-immunostaining of Dysbindin (red) with Myozap (green) in untreated neonatal rat cardiomyocytes (MRVCMs) is shown. Nuclei were stained with DAPI (blue), and the immunofluorescence images were captured on a Zeiss LSM 510 confocal microscope.

Co-immunostaining of Dysbindin (red) with Myozap (green) in endothelin-1-treated neonatal rat cardiomyocytes (NRVCMs). Nuclei were stained with DAPI (blue), and the immunofluorescence images were captured on a Zeiss LSM 510 confocal microscope.

A representative image exemplifying the phenotype of MEK1 inhibitor-treated neonatal rat cardiomyocytes infected with Ad-LacZ is shown.

A representative image exemplifying the phenotype of untreated neonatal rat cardiomyocytes infected with Ad-Dysbindin is shown.

A representative image exemplifying the phenotype of neonatal rat cardiomyocytes (NRVCMs) shows the effect of Dysbindin overexpression. NRVCMs were cultured on coverslips in triplicate, infected with Ad-Dysbindin for 72 hr, and immunostained with α-actinin (red). Nuclei were stained with DAPI (blue).

Co-immunostaining of Dysbindin (red) with RhoA (green) in phenylephrine-treated neonatal rat cardiomyocytes (NRVCMs). Nuclei were stained with DAPI (blue), and the immunofluorescence images were captured on a Zeiss LSM 510 confocal microscope.

Co-immunostaining of Dysbindin (red) with RhoA (green) in untreated neonatal rat cardiomyocytes (NRVCMs). Nuclei were stained with DAPI (blue), and the immunofluorescence images were captured on a Zeiss LSM 510 confocal microscope.

A representative image exemplifying the phenotype of neonatal rat cardiomyocytes (NRVCMs) shows the effect of Dysbindin overexpression in the presence of phenylephrine treatment. NRVCMs were cultured on coverslips in triplicate, infected with Ad-Dysbindin for 72 hr, treated with phenylephrine, and immunostained with α-actinin (red). Nuclei were stained with DAPI (blue).

A representative image exemplifying the phenotype of untreated neonatal rat cardiomyocytes infected with Ad-LacZ is shown.

Co-immunostaining of Dysbindin (red) with Myozap (green) in phenylephrine-treated neonatal rat cardiomyocytes (NRVCMs). Nuclei were stained with DAPI (blue), and the immunofluorescence images were captured on a Zeiss LSM 510 confocal microscope.

A representative image exemplifying the phenotype of control neonatal rat cardiomyocytes (NRVCMs) is shown. NRVCMs were cultured on coverslips in triplicate, infected with Ad-LacZ for 72 hr and immunostained with α-actinin (red). Nuclei were stained with DAPI (blue).

bioimagesFigure 3 - DImage 575159 (Figure 6 - C)Supplemental Figure 1 - CSupplemental Figure 1Image 574765 (Figure 3 - D)Image 575164 (Figure 7 - E)Image 574762 (Figure 1 - D)Image 575214 (Supplemental Figure 1 - C)Figure 7 - EImage 575165 (Figure 7 - E)Image 575215 (Figure 6 - C)Image 574760 (Figure 1 - D)Image 574763 (Figure 3 - D)Figure 1 - DImage 575166 (Figure 7 - E)Image 575158 (Figure 6 - C)Image 574761 (Figure 1 - D)Figure 7Figure 6Image 574764 (Figure 3 - D)Figure 6 - CFigure 1Image 575157 (Figure 6 - C)Figure 3Image 575167 (Figure 7 - E)Derk FrankAlexander BerntChristian KuhnAshraf Yusuf RangrezInka BoomgaardenAstrid RohrbeckReza PoyanmehrVioletta HarazinNorbert FreyfalseDysbindin is a potent inducer of RhoA–SRF-mediated cardiomyocyte hypertrophy2013-11-25T11:25:02Z2018-11-29T11:25:02Z2018-11-29T11:25:02ZS-JCBD-20130305210.1083/jcb.201303052